Genetic analysis for stratification and discovery in dementia patients by extending the NOMALY framework to non-coding variation

通过将 NOMALY 框架扩展到非编码变异，对痴呆症患者进行分层和发现的遗传分析

• 批准号: 10073100
• 金额: $ 49.73万
• 依托单位: OUTSEE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10073100
• 关键词: Genetic; analysis; stratification; discovery; dementia

OutSee Limited working with Astex Pharmaceuticals will be unlocking value and insights in non-coding genomic data through the _Nomaly_ approach to support precision medicine for dementia patients. We will be developing new AI to tackle the non-coding part of the genome alongside discovery developed on the protein-coding variation in the genome. Dementia is a heterogeneous condition and includes multiple subtypes affecting memory, behaviour and cognitive abilities. Patient stratification into distinct subgroups is key to optimise treatment options so that interventions can be offered to those who will benefit the most and identify patient subgroups who are at risk. Subsequently, it would improve the clinical outcomes and reduce risks of adverse effects.

OutSee Limited与Astex Pharmaceuticals合作，将通过_Nomaly_方法释放非编码基因组数据的价值和见解，以支持痴呆症患者的精准医疗。我们将开发新的人工智能来解决基因组的非编码部分，同时发现基因组中的蛋白质编码变异。痴呆症是一种异质性疾病，包括影响记忆、行为和认知能力的多种亚型。将患者分层为不同的亚组是优化治疗方案的关键，以便为受益最大的患者提供干预措施，并确定处于风险中的患者亚组。随后，它将改善临床结果并降低不良反应的风险。